Acadia Raises 2026 Sales Outlook After DAYBUE Acceleration

The Tip Desk · August 5, 2026 · 3 min read

Second-quarter revenue reached $308 million as DAYBUE net sales hit $125 million and the company lifted full-year guidance to as much as $1.30 billion.

Acadia Pharmaceuticals Inc. (ACAD) raised its 2026 total revenue outlook to $1.24 billion to $1.30 billion after DAYBUE sales accelerated and NUPLAZID growth picked up, a step-up from the $1.22 billion to $1.28 billion range it had set in February.

The rare-disease and neurology company posted GAAP total revenues of $308 million for the second quarter ended June 30, 2026, up 16% from $265 million a year earlier and 17% versus non-GAAP adjusted revenues of $262 million. Sequentially, that total was up from $268 million in the first quarter, when GAAP growth had been 10%. Chief Executive Officer Catherine Owen Adams said the quarter showed strong commercial execution across both products and 17% year-over-year growth on an adjusted basis.

DAYBUE was the inflection point. GAAP net sales were $125 million, up 30% from $96 million a year earlier, after 20% growth in the first quarter. The second-quarter increase reflected strong uptake of DAYBUE STIX, the powder formulation that began its U.S. launch in the prior quarter. First-quarter DAYBUE sales were $101 million. Full-year DAYBUE guidance, including all forms of trofinetide, moved to $480 million to $510 million from $460 million to $490 million.

NUPLAZID GAAP net sales were $183 million, up 9% from $168 million a year earlier and 10% versus non-GAAP adjusted sales of $166 million. Adjusted year-over-year growth was 10% after 6% in the first quarter, when GAAP NUPLAZID sales were $167 million. Adams said momentum continued, especially in new-to-brand prescriptions, as the recently expanded sales force gained traction. Full-year NUPLAZID guidance was reaffirmed at $760 million to $790 million.

Net income was $32 million, or $0.18 a share, compared with $27 million, or $0.16 a share, a year earlier. That followed $4 million, or $0.02 a share, in the first quarter. Selling, general and administrative expenses were $160 million, down from $171 million in the first quarter. Research and development expenses were $82 million. Full-year R&D expense guidance was lowered to $355 million to $380 million from $385 million to $410 million; SG&A guidance was $660 million to $700 million.

Cash, cash equivalents, and investment securities totaled $956 million at June 30, 2026, compared with $820 million at year-end 2025. Accounts receivable were $151 million.

The company completed enrollment in the Phase 2 portion of the RADIANT program evaluating remlifanserin in Alzheimer’s disease psychosis and initiated Phase 3 screening and enrollment. Topline Phase 2 results are now expected in September to October 2026, a narrower window than the August-to-October range stated in the first-quarter update. The company received FDA Fast Track designation for remlifanserin for hallucinations and delusions associated with Alzheimer’s disease psychosis. Adams said the company believes those results represent a potentially transformational opportunity.

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorization for DAYBU (trofinetide) for neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five and older. If approved by the European Commission, DAYBU would become the first authorized treatment for Rett syndrome in the European Union.

Adams said the company remains confident that both franchises are on track to achieve its long-term ambition of approximately $1.7 billion in annual net sales in 2028.